Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.
"This is a significant safety milestone for the company, being the first time a citrullinated peptide vaccine from our Moditope platform has been given to cancer patients. We are encouraged that there were no safety concerns in the initial cohort, allowing us to proceed smoothly with the dose escalation," says Chief Executive Officer Lindy Durrant.
Current stock price: 13.25 pence, up 4.3% on Tuesday
12-month change: down 35%
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)